In Cuevas v. Contra Costa County, the California First District Court of Appeal held that a jury deciding future medical damages in a medical malpractice case can hear evidence about Affordable Care Act insurance benefits and the discounted rates providers actually accept, rather than being limited to full billed charges. The April 27, 2017 decision reversed a roughly $100 million future-care award and sent the damages question back for a new trial, while leaving the negligence finding against the county’s physicians untouched.111 Cal.App.5th 163 (2017)
What the Court Decided
The appeal turned on three questions about how a jury should value future medical care. On each, the trial court had ruled for the plaintiff, and on each, the Court of Appeal reversed.
ACA Evidence Belongs Before the Jury
At trial, the defense offered testimony from expert Thomas J. Dawson, who opined that the ACA was likely to remain in force for Brian Cuevas’s lifetime and identified specific California insurance plans that could cover his care. The trial court excluded the testimony, calling the ACA’s future too speculative.
The appellate court called that an abuse of discretion. The ACA was established law, the defense had laid a foundation by identifying real plans, and evidence supporting the statute’s continued viability should have gone to the jury to weigh. Justice Banke authored the opinion, joined by Presiding Justice Humes and Justice Margulies.
MICRA Reaches Future Collateral Source Benefits
Civil Code section 3333.1, part of California’s Medical Injury Compensation Reform Act, allows defendants in malpractice cases to introduce evidence of benefits a plaintiff receives from collateral sources such as insurance. The trial court read the statute to cover only past benefits. The Court of Appeal read it more broadly: the phrase “amount payable” is wide enough to reach future benefits, and admitting that evidence fits MICRA’s purpose of reducing duplicative damages and holding down malpractice insurance costs.
Reasonable Value, Not Billed Charges
Building on Howell v. Hamilton Meats & Provisions, Inc. (2011) and Corenbaum v. Lampkin (2013), the court affirmed that the reasonable value of future medical services is what a provider is actually likely to accept as payment, not what a provider bills. Evidence of the discounted rates insurers negotiate with providers is admissible to help a jury find that value, so long as the defendant does not specifically name a protected collateral source such as Medi-Cal. The collateral source rule still shields Medi-Cal benefits, which carry a government right of reimbursement and are treated differently.
How the Case Reached the Court
Brian Cuevas was born on June 27, 2008, the surviving twin of a high-risk monochorionic-diamniotic pregnancy managed by Dr. Teresa Madrigal, a family practitioner employed by Contra Costa County Health Services. During the pregnancy and delivery, Brian suffered a hypoxic brain injury that caused irreversible damage. He was left with cerebral palsy, a very low verbal IQ, serious language and communication difficulties, significant behavioral problems, and severe developmental delays, and will require lifelong assistance and round-the-clock attendant care.
The suit alleged that Dr. Madrigal was unqualified to manage the pregnancy, missed specific risk factors including twin-to-twin transfusion syndrome and marginal cord insertion, allowed the pregnancy to continue past 37 weeks when earlier delivery was indicated, and, with Dr. Scott Loeliger, delayed transport for an emergency cesarean section on the morning of delivery. Contra Costa Health Services accepted liability for its employees.
On September 18, 2014, the jury returned a unanimous verdict on negligence and damages and voted 11-1 on causation. The total present-value award was $12,132,780.82. The jury awarded $100 million for future medical, hospital, surgical, and rehabilitation care, then reduced that to a present cash value of $9,577,000. Counsel estimated the total projected future value of the verdict at more than $112 million.
That $100 million figure sat between the two life care planners. The plaintiff’s expert, Jan Roughan, had put total future care at roughly $285 million, with a present value near $29 million, using national databases of average billed charges at the 80th percentile. The defense expert, Linda Olzack, put the present value of future care between $3.2 million and $3.3 million under various scenarios. The pricing gap is what made the evidentiary rulings decisive.
What Changed for Future Damages Calculations
After Cuevas, defendants in California medical malpractice cases can present evidence that a plaintiff’s future care will be paid, at least in part, through ACA-marketplace insurance, and can ask the jury to value that care at the discounted rates providers accept from insurers rather than at full retail. The court approved “Usual, Customary and Reasonable” pricing measured through national price surveys at the 80th percentile of actual charges, giving both sides a workable framework.
The line between admissible pricing evidence and speculative projection stayed contested. Roughan testified that private insurance discounts fluctuate widely and that no definable or typical discount percentage exists. Richard Lievense, the plaintiff’s health insurance expert, testified that the ACA could not be assumed to provide benefits for the length of Brian’s projected 74-year life expectancy. Even Olzack acknowledged she could not be certain that ACA-plan discounts would hold for more than a few years. A defense expert who wants to use specific insurance discounts still has to tie the coverage to the plaintiff’s life expectancy and show with reasonable certainty that it will persist, which is a heavy lift for injuries requiring decades of care.
How Far Cuevas Reaches
Defense attorneys have cited Cuevas in personal injury cases outside malpractice, arguing that discounted insurance rates represent the true market value of future medical care generally. That extension is debatable: the ruling leaned heavily on MICRA’s collateral source provision, Civil Code section 3333.1, which applies only to medical malpractice actions.
The 2022 MICRA amendments in Assembly Bill 35, signed by Governor Gavin Newsom, raised the cap on noneconomic damages and adjusted other provisions but did not touch the collateral source questions at the center of Cuevas. Whether and how future ACA benefits offset a damages award in a California malpractice case is still governed by the First District’s 2017 opinion.